Classifications: substance abuse deterrent; Therapeutic:substance abuse inhibitor
Pregnancy Category: C
333 mg delayed-release tablets
May interact with CNS glutamate and GABA neurotransmitter systems and help restore normal balance between neuronal excitation
and inhibition. Acamprosate is a neurotransmitter analog.
Reduces craving for alcohol intake due to chronic use, but does not cause alcohol aversion or a disulfiram-like reaction
as a result of ethanol ingestion.
Maintenance of abstinence from alcohol in patients with alcoholism.
Hypersensitivity to acamprosate calcium or any of its components; suicidal ideation; pregnancy (category C). Safety and
efficacy in patients with severe renal impairment (Clcr <30 mL/min) have not been established.
Moderate renal impairment; depression; lactation. Safety and efficacy of acamprosate have not been established in adolescents
or children <18 y.
Route & Dosage
|Maintenance of Alcohol Abstinence
Adult: PO 666 mg t.i.d.
Adult: PO Clcr 3050 mL/min: 333 mg t.i.d.; <30 mL/min: do not use
- Ensure that the drug is not chewed or crushed. It must be swallowed whole.
- Store at 15°30° C (59°86° F).
Adverse Effects (≥1%)Body as a Whole:
Flu syndrome, chills. CNS: Depression
, anxiety, insomnia
, asthenia, dizziness, paresthesia, headache, somnolence, decreased libido, amnesia, abnormal
thinking, tremor. CV:
Palpitation, syncope. GI: Diarrhea,
nausea, vomiting, anorexia, flatulence, dry mouth, abdominal pain, dyspepsia, constipation
, increased appetite. Metabolic:
Peripheral edema, weight gain. Musculoskeletal:
Musculoskeletal pain. Respiratory:
Rhinitis, cough, dyspnea, pharyngitis, bronchitis
Pruritus, diaphoresis, rash. Special Senses:
Abnormal vision, taste perversion. Urogenital:
11% bioavailability. Metabolism:
Not metabolized. Elimination:
Assessment & Drug Effects
- Monitor for S&S depression or suicidal thinking.
- Monitor for dizziness or impaired judgment, thinking, and motor skills; take appropriate protective measures.
Patient & Family Education
- Report any alcohol consumption while taking acamprosate.
- Report promptly any of the following: unusual anxiousness or nervousness; depression or suicidal thoughts; burning or tingling
sensations in arms, legs, hands, or feet; chest pains or palpitations; difficulty urinating.
- Do not drive or engage in other hazardous activities until reaction to the drug is known.